2.0 Million
Received Buprenorphine Medication Assisted Treatment (BMAT)1
4.0 Million
People diagnosed with OUD in the U.S.2
7.1 Million
People misuse opioids in the U.S.2
Our Products
Our products are rooted in science, compassion and an unwavering commitment to help people with opioid use disorder (OUD) achieve long-term recovery.
Our Science
We lead the way in developing long-term treatment options for people who suffer from opioid use disorder (OUD), addressing the most urgent public health challenges of our time.
Our Impact
We advocate for systemic change by working with policymakers, healthcare systems, justice institutions, and advocacy groups to eliminate stigma and barriers to OUD recovery.
Our Focus
Our focus is singular and unwavering: to transform the lives of people affected by opioid use disorder (OUD) through the power of science, compassion, and advocacy.
Article feed
-
Long-Acting Injectable Buprenorphine Treatment for Opioid Use Disorder Explained
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST.
Read more -
1. Symphony and Indivior analytics, patient treated over the last twelve months.
